Ardian reinvests in Neopharmed Gentili alongside NB Renaissance

• Neopharmed Gentili implemented a buy-and-build plan since Ardian backed it
• The company has diversified its product portfolio, achieving revenues of €250 million
• Alessandro Del Bono will continue to lead the company as CEO

Ardian announced on Wednesday that it has reinvested in Neopharmed Gentili, with NB Renaissance joining as an investor.  They will jointly hold a majority stake with equal shares. Pharmaceutical firm Mediolanum Farmaceutici will retain a significant portion of the group’s shareholding.

Ardian first invested in Milan-based Neopharmed in November 2018. The company sells pharmaceutical products in the Italian market. With the backing of Ardian, Neopharmed achieved organic growth and implemented a buy-and-build plan, resulting in six M&A transactions in four years. The company has diversified its product portfolio, achieving revenues of €250 million. Alessandro Del Bono will continue to lead Neopharmed following the reinvestment.

“Thanks to the work of the management team and the support of Ardian, the company has been able to embark on a path of solid organic and inorganic growth over the past four years,” said Nicolò Saidelli, deputy head, buyout team, Ardian. “We are convinced that Neopharmed has numerous growth opportunities in Italy and abroad and we believe that the partnership with NB Renaissance will facilitate the plan of further consolidation and international development.”

Paris-headquartered Ardian is a private investment firm that manages or advises $141 billion of assets on behalf of more than 1,300 clients globally. It invests across private equity, real assets and credit.

NB Renaissance is a Milan-headquartered investment firm that invests in international companies based in Italy. The firm manages over €2.3 billion in assets and is invested in 13 companies with an aggregate turnover of approximately €6 billion.